GSK plc (GSK) announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).The study achieved its primary endpoint of non-inferior immune response — study participants who received the co-administered shot generated immune responses that were similar to those generated in participants who received each vaccine separately. Study participants who received th ...